Researchers have long been recognizing the uniqueness of women’s health and the substantial effect on clinical practice, acknowledging the increasing appreciation of the importance of multidisciplinary approaches to health and disease. In every organ system, there are diseases that are unique to women, more common in women than in men, or characterized by differences in disease course in women compared with men. This session will include the effect of women’s health on the following topics:
Dr. Aleksandar Rajkovic serves as the UCSF Chief Genomics Officer and is the Medical Director and Chief of the Center for Genetic and Genomic Medicine (CGGM) that organizes, coordinates and oversees Clinical Genetics and Genomics Services across the entire UCSF Health System. He also serves as the Director of the Genomic Medicine Initiative. He is also Stuart Lindsay Distinguished Professor in Experimental Pathology I, member of the American Society of Clinical Investigation and American Association of Physicians. His research interests lie in basic and translational medical sciences in the area of reproductive genetics. Dr. Rajkovic discovered numerous genes that play critical roles in reproductive tract development, male and female infertility, and uterine tumors. He has been at the forefront of applying cutting edge genomic technologies to reproductive diagnostics, including prenatal diagnosis, preimplantation genetic screening, and perinatal genomics. He has made significant contributions to non-invasive diagnosis of submicroscopic deletions, design and utility of dense X chromosome arrays, and utility of genome wide detection of copy number variants in prenatal diagnosis. His current interests lie in whole genome applications towards population based health prediction and prevention, as well as prevention of Mendialian disorders.
Dr. Rosenblatt leads the clinical assay development efforts for NX Prenatal, leveraging more than 29 years of clinical and biomedical research and development experience in multiple settings, including academia, biotech, startups, and clinical practice. Prior to joining NX Prenatal, he was Chief Scientific Officer, Chief Medical Officer, and Clinical Laboratory Director at CompanionDx's CLIA/CAP certified reference lab. Among other appointments, he has served as Director of the Center for Clinical Proteomics at the Brown Foundation Institute of Molecular Medicine, as well as the Director of the UT Health Science Center at Houston's Center for Clinical and Translational Sciences Proteomics Core. Dr. Rosenblatt also serves as Associate Professor in the Division of Oncology, Department of Internal Medicine at UT Health and the McGovern Medical School and Associate Adjunct Professor in the School of Health Professions at the MD Anderson Cancer Center. Earlier in his career, Dr. Rosenblatt was co-founder and Laboratory Director of Risk Assessment Laboratories, which partnered with Perkin-Elmer to develop adverse pregnancy outcome biomarkers.
Women's Health Showcase:
NX Prenatal utilizes proprietary exosome-based liquid biopsy techniques to create breakthroughs in maternal-fetal diagnostics. Our NeXosome® Platform has yielded Preterm Birth and Preeclampsia biomarker panels at week 10-12 of pregnancy in asymptomatic women to support personalized care pathways.
Exosomes: Decoding Maternal-Fetal Cross Talk
Maternal-fetal cross-talk is mediated by exosomes, which actively support a number of physiological systems, including regulating the immune protection of the fetus. NX Prenatal has demonstrated that the profiling of exosomal-bound proteins circulating in pregnant women provides early markers predicting preterm birth and preeclampsia, and also provides new insight into the molecular pathways associated with such outcomes.